www.bioscience.co.uk
Sales & Support: +44 (0)1223 316 855

*

C5/C5a, Human, mAb 557

Catalogue number:
HM2077-100UG
Supplier:
Size:
100 µg _$$_
Product is available in:
  • UK
  • Ireland
  • Europe
  • USA
  • Rest of World
£410.00 Shipping is calculated in checkout
Applications:

Functional studies, Immuno assays, Western blot

Immunogen:

BALB/c mice were immunized with human C5

Product Description:

The monoclonal antibody 557 recognizes an epitope of complement factor 5 (C5) and C5a. The complement system is composed of over 30 proteins, activated in response to tissue injury, invading pathogens or other foreign surfaces. The complement pathways can be divided in the activation pathways and lytic pathway.The activation pathways lead via C3 to the cleavage of the fifth complement component C5. C5a was first described as a cleavage product of C5 with chemotactic and anaphylatoxic properties. Further characterization revealed that C5a is an essential part of the innate immune response and evidence now suggests that it may also play a role in adaptive immunity. Complement fragment C5a is a 74 residue pro-inflammatory polypeptide. C5a induces smooth muscle contraction, increases vascular permeability, causes degranulation of mast cells and basophils, and release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. C5a binds to at least two seven-transmembrane domain receptors, C5aR (C5R1, CD88) and C5L2 (gpr77), expressed ubiquitously on a wide variety of cells but particularly on the surface of immune cells like macrophages, neutrophils and T cells. The former is a well-established receptor that initiates G-protein-coupled signaling via mitogen-activated protein kinase pathways, thereby by inducing synthesis of cytokines such as TNF-alpha, IL-1beta,- IL-6 and IL-8. Its in vivo blockade greatly reduces inflammatory injury. Much less is known about C5L2, occupancy of which by C5a does not initiate increased intracellular Ca(2+).The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases. Nowadays C5a is also implicated in non-immunological functions associated with developmental biology, CNS development and neurodegeneration, tissue regeneration, and haematopoiesis.The antibody 557 is capable to inhibit the binding of C5a to the C5a receptor through a competitive mechanism, it does not block the cleavage of C5 into C5a and C5b.

HM2077-100UG C5/C5a, Human, mAb 557
HM2077-100UG C5/C5a, Human, mAb 557
Details Cat number & supplier Size Price
C5a/C5a des Arg, Human, mAb 2942 HM2078-100UG · Hycult Biotech
HM2078-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C5/C5a, Human, mAb 561 HM2076-100UG · Hycult Biotech
HM2076-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C5a/C5a des Arg, Human, mAb 2952 HM2079-100UG · Hycult Biotech
HM2079-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3/C3a, Human, mAb 2898 HM2075-100UG · Hycult Biotech
HM2075-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C5/C5b, Human, mAb 568 HM2080-100UG · Hycult Biotech
HM2080-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3a/C3a des Arg, Human, mAb 2991 HM2074-100UG · Hycult Biotech
HM2074-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
SAA-1, Human, mAb Reu86.1 HM2100-100UG · Hycult Biotech
HM2100-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3/C3a, Human, mAb 474 HM2073-100UG · Hycult Biotech
HM2073-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
SAA-1, Human, mAb Reu86.5 HM2101-100UG · Hycult Biotech
HM2101-100UG
Hycult Biotech
100 µg £410.00
100 µg
view
C3/C3b, Human, mAb 755 HM2072-100UG · Hycult Biotech
HM2072-100UG
Hycult Biotech
100 µg £410.00
100 µg
view